About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 1475 record(s)
Req # A-2021-000429
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100879-962.Organization: Health Canada
January 2022
Req # A-2021-000432
Adverse Drug Reactions (ADRs) for Abilify. Report numbers: 000935127, 000936589, 000940527, 000941548, E2B_03725761, E2B_03776286. ADRs for ABILIFY MAINTENA. Report numbers: 000940110, 000941549, 000945768, E2B_03711298. ADRs for ARIPIPRAZOLE. Report numbers: 000938706, 000938832, 000940097, E2B_03783692.Organization: Health Canada
January 2022
Req # A-2021-000531
Adverse Drug Reactions (ADRs). Report numbers: E2B_03785268, E2B_03810372, E2B_03826339, E2B_03833889, E2B_03840727, E2B_03840754, E2B_03840947, E2B_03841105, 000940658, 000943226, E2B_02140757, E2B_03435555, E2B_03522377, E2B_03598406, E2B_03740870, E2B_03746706, E2B_03788029, E2B_03790742, E2B_03812516, E2B_03821812.Organization: Health Canada
January 2022
Req # A-2021-000533
Adverse Drug Reactions (ADRs). Report numbers: E2B_03788263, E2B_03790742, E2B_03801130, E2B_03809929, E2B_03812516, E2B_03812854, E2B_03812908, E2B_03816559, E2B_03818876, E2B_03819094, E2B_03822634, E2B_03830467, E2B_03830534, E2B_03833787, E2B_03833843, 000908829, 000909010.Organization: Health Canada
January 2022
Req # A-2021-000615
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-075429-278, Meeting with Diabetes Canada - September 25, 2020.Organization: Health Canada
January 2022
Req # A-2021-000616
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-075601-626, Meeting with Diabetes Canada: November 15, 2019.Organization: Health Canada
January 2022
Req # A-2021-000686
Adverse Drug Reactions (ADRs). Report numbers: E2B_03895773, E2B_03915037, E2B_01646091.Organization: Health Canada
January 2022
Req # A-2021-000726
Adverse Drug Reactions (ADRs) for Prevegyne (ascorbic acid). Report numbers: E2B_03761224, E2B_03851950, E2B_03838138.Organization: Health Canada
January 2022
Req # A-2021-000810
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03511469, E2B_03487199, E2B_03421679, E2B_03399481, E2B_03462367, E2B_03279959.Organization: Health Canada
January 2022
Req # A-2021-000815
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03436602, E2B_03481725, E2B_03433407, E2B_03489388, E2B_03486051, E2B_03490790, E2B_03511361, E2B_03495491, E2B_03515797, E2B_03373288, E2B_03353225, E2B_03511582, E2B_03423676, E2B_03331692, E2B_03425643, E2B_03426404, E2B_03296809, E2B_03477964, E2B_03447219, E2B_03455228.Organization: Health Canada
January 2022